Refractory, primary Central Nervous System Neoplasm Recruiting Phase 2 Trials for Sulfate ion (DB14546)
Also known as: Refractory Primary Central Nervous System Neoplasm
| Indication | Status | Phase |
|---|---|---|
| DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm) | Recruiting | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Screening |
|
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Treatment |